Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Therapy for Metastatic Renal Cell Cancer
NCT02560012Phase 2Terminated
- Sponsor
- UTHealth Houston
- Start
- Jan 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib, temsirolimus, sorafenib, pazopanib, everolimus in renal cell carcinoma (RCC), sponsored by UTHealth Houston. Started Jan 2016; status: terminated.
02
Drugs
sunitinibtemsirolimussorafenibpazopanibeverolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02560012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560012.